返回Google圖書搜尋

Optimizing Point-of-Care Testing Strategies for Diagnosis and Treatment of Hepatitis C Virus Infection in Australia

Sophy TF ShihQinglu ChengJoanne CarsonHeather ValerioYumi SheehanRichard T. GrayEvan B. CunninghamJisoo KwonAndrew R. LloydGregory J. DoreVirginia WisemanJason Grebely

其他書名	A Model-Based Cost-Effectiveness Analysis
出版	SSRN, 2023
URL	http://books.google.com.hk/books?id=pjLyzwEACAAJ&hl=&source=gbs_api

註釋Background: Timely diagnosis and treatment of hepatitis C virus (HCV) is critical to achieve elimination goals. This study evaluated the cost-effectiveness of point-of-care testing strategies for HCV compared to laboratory-based testing in standard of care.Methods: Cost-effectiveness analyses were undertaken from the perspective of Australian Governments as funders by modelling point-of-care testing strategies compared to standard of care in needle and syringe programs, drug treatment clinics, and prisons. Point-of-care testing strategies included immediate point-of-care HCV RNA testing and combined point-of-care HCV antibody and reflex RNA testing for HCV antibody positive people (with and without consideration of previous treatment). Sensitivity analyses were performed to investigate the cost per treatment initiation with different testing strategies at different HCV antibody prevalence levels.Findings: The average costs per HCV treatment initiation by point-of-care testing were up to 35% lower (A$890-A$1,406) compared to standard of care (A$1,248-A$1,632) depending on settings. The average costs per treatment initiation by point-of-care testing were A$1,080-A$1,406 for RNA, A$960-A$1,310 for combined antibody/RNA without treatment history consideration, and A$890- A$1,189 for combined antibody/RNA with treatment history consideration. When HCV antibody prevalence was